Ingrid Lönnstedt: What does the p-value mean?

The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significa...

ZEISS supports the transition of spatial biology to clinical research

Slide scanner ZEISS Axioscan 7 spatial biology provides scalable workflow automation.

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

Explore the latest trends and innovations in quality assurance and manufacturing

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Abbvie förvärvar lovande projekt inom psykisk ohälsa

Abbvie köper ett läkemedelsprogram inom mental hälsa i en miljardaffär som ser lite annorlunda än vad som tidigare uppgetts.

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...

Klartecken för första läkemedlet mot lungsjukdomen NCFBE – väntas bli en blockbuster

Det första läkemedlet i en helt ny klass, DPP1-hämmare, har godkänts i USA. Det är det första sjukdomsmodifierande läkemedlet mot bronkiektasier utan cystisk fi...

The life science strategy – what the industry wants

The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s compe...

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”

It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless differ...

Pharma Relations AB

Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell

Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Mich...

Medical Plastics Tips & Tricks

Measuringhero video by ZEISS.

Join our measuringhero Jay on the innovation tour

Experience our latest innovation from the Control fair.

On the hunt for high throughput diagnostics

Global diagnostics companies and laboratories are in a race against time to adapt testing capacity to current demand. Due to the global COVID 19 pandemic, the d...

Beta-blockers are often given unnecessarily, a study finds – “This will affect future practice”

Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.

Samuel Lagercrantz: “Companies that do this successfully will take the lead”

The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

Merck Life Science A/S

How to optimise your liquid handling results

In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...

Metabolon

Come see us at the upcoming events!

We have some upcoming events where you can see our latest products live!

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients...